The GH axis — in 90 seconds
Growth hormone is released from the pituitary in pulses. Two natural inputs control those pulses:
- GHRH (growth hormone releasing hormone) — the "go" signal from the hypothalamus.
- Ghrelin — a second amplifier that synergizes with GHRH and silences somatostatin (the brake).
Modern peptide protocols mimic these inputs. GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) push the "go" pedal. GHRP / ghrelin mimetics (Ipamorelin, Hexarelin, GHRP-2/6, MK-677) amplify the pulse. Stacking one from each class produces a bigger, cleaner pulse than either alone — that's the whole reason CJC + Ipa exists as a category.
Hexarelin + CJC vs Ipamorelin — the honest comparison
This is the question we get most often, and it's where most programs get it wrong.
Hexarelin + CJC-1295 (no DAC)
Strongest GH release of the major stacks. Hits both sides of the axis at once. Real, visible recomposition in higher responders.
- Largest GH pulses in the GHRP family
- Noticeable recovery improvement
- Deep-sleep enhancement
- Faster tendon and muscle repair
- Desensitizes fast — this is a big deal
- Elevates prolactin and cortisol more than ipamorelin
- Water retention, hunger spikes, possible lethargy
- Requires tight cycling — not a casual peptide
→ Tactical weapon, not a daily driver.
Ipamorelin (selective GHRP)
A much cleaner ghrelin-receptor signal. Smaller pulses, smoother profile. Almost no cortisol or prolactin elevation.
- Very low side-effect profile
- Good sleep support
- Mild fat loss + recovery support
- Easy to tolerate long-term
- Weaker subjective & visible results
- Slower changes
- Less impressive for high-performance clients
→ The retention-friendly base for almost every member.
Hexarelin's problem: clients feel it fast and love it — until tolerance builds and results fade. They blame the product. It's not a sales issue, it's pharmacology.
Ipamorelin's problem: clients don't "feel" much, decide it's weak, and quit early. Same outcome, different reason.
The right answer isn't picking one. It's pairing the right molecule to the right person at the right phase. That's what protocols do.
CJC-1295: DAC vs no-DAC
This single choice shapes whether your stack is physiologic or pharmacologic.
No DAC (modified GRF 1-29)
- Pulsatile — mimics natural release
- Synergizes properly with GHRP timing
- Requires multiple daily injections
Correct call for performance, recovery, and longevity stacks.
DAC (drug affinity complex)
- Long-acting — flat, elevated GH bleed
- Less physiologic — chronic exposure has real downsides
- Higher water retention risk
Only used in very specific clinical contexts — not our default.
Tier 1 → Tier 3 — clinic-style segmentation
A peptide stack that works for one client can wreck another. We segment members into three tiers based on goals, history, and tolerance.
CJC-1295 (no DAC) + Ipamorelin
Recovery, sleep, anti-aging. Long-term safe. The retention anchor.
CJC + Ipa baseline · rotated stronger GHRPs (short cycles)
Better, more sustainable than chronic hexarelin. We avoid continuous strong GHRPs because of desensitization.
Hexarelin + CJC no-DAC · 2–4 weeks max
For injury recovery, plateau breaking, and aggressive recomposition phases. Premium protocol — never daily use.
GLP-1, GLP-2, GLP-3 — the metabolic ladder
Different drugs, different receptor coverage, different real-world response profiles.
| Program | Molecule | Mechanism | Best for |
|---|---|---|---|
| GLP-1 | Semaglutide | GLP-1 receptor agonist | Steady fat loss, well-tolerated entry point |
| GLP-2 | Tirzepatide | Dual GLP-1 + GIP agonist | Greater fat loss + insulin sensitivity in most patients |
| GLP-3 | Retatrutide | Triple GLP-1 + GIP + glucagon agonist | Aggressive recomposition; advanced patients only |
Pairing CJC + Ipamorelin alongside any GLP program helps preserve lean mass during caloric deficit — a common gap in metabolic-only stacks.
Repair & recovery peptides
BPC-157
Body protective compound — systemic and gut healing, tendon support, anti-inflammatory.
TB-500 (Thymosin β4)
Tissue repair, vascularization, mobility recovery.
GHK-Cu
Skin remodeling, collagen synthesis, anti-aging.
KPV
Anti-inflammatory tripeptide; gut and skin support.
Cartalax
Bioregulator targeting cartilage synthesis — joint longevity.
MOTS-C
Mitochondrial-derived peptide; metabolic and exercise capacity support.
Nootropic peptides
Semax (AM)
Nasal heptapeptide. Focus, cognitive performance, dopamine balance — without the stimulant crash.
Selank (PM)
Anxiolytic peptide. Anxiety control, mood stabilization, better sleep quality.
Why we dose men and women differently
It's not that women need "less of the same thing." Priorities are different — skin, hormonal stability, low side-effect tolerance — and dose-response curves are different too.
- Women generally start at lower CJC + Ipa doses; the lighter pulse is sufficient and avoids unwanted hunger/water retention.
- We do not push hexarelin broadly to female members — the prolactin profile is the wrong tradeoff for most goals.
- The Glow protocol (GHK-Cu + BPC-157 + TB-500 + KPV) is our most-requested female stack and consistently delivers visible skin/hair changes within 6–12 weeks.
Safety, sourcing, and what we won't do
- All medications are dispensed by an independent, licensed compounding pharmacy.
- We do not stack hexarelin chronically. Period.
- We do not push protocols to members for whom the risk/benefit is wrong (pregnancy, certain endocrine conditions, etc.). Eligibility is a clinician decision.
- We will tell you when a protocol won't work for your goal — even if it costs us a sale.
This page summarizes our internal research notes and is for education. It is not medical advice. Eligibility and dosing are determined by a licensed clinician for each member.
Ready to put research into practice?
See the protocols we build from these mechanisms.